Cargando…

IP6K2 predicts favorable clinical outcome of primary breast cancer

The inositol hexakisphosphate kinase (IP6K) 1 and 2 genes are localized at 3p21.31, a highly altered gene-dense chromosomal region in cancer. The IP6Ks convert IP6 to IP7, which inhibits activation of the tumor-promoting PI3K/Akt/mTOR signaling pathway. IP6K2 has been suggested to be involved in p53...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sandström, Josefine, Balian, Alien, Lockowandt, Rebecca, Fornander, Tommy, Nordenskjöld, Bo, Lindström, Linda, Pérez-Tenorio, Gizeh, Stål, Olle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7976380/ https://www.ncbi.nlm.nih.gov/pubmed/33767863 http://dx.doi.org/10.3892/mco.2021.2256

Ejemplares similares

The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials
por: Karlsson, Elin, et al.
Publicado: (2013)

The effects of PTPN2 loss on cell signalling and clinical outcome in relation to breast cancer subtype
por: Veenstra, Cynthia, et al.
Publicado: (2019)

RAB6C is an independent prognostic factor of estrogen receptor-positive/progesterone receptor-negative breast cancer
por: Fohlin, Helena, et al.
Publicado: (2020)

Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor-positive/progesterone receptor-negative breast cancer
por: Fohlin, Helena, et al.
Publicado: (2020)

Assessment of 25-Year Survival of Women With Estrogen Receptor–Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial
por: Dar, Huma, et al.
Publicado: (2021)

Clinical and molecular characteristics of estrogen receptor‐positive ultralow risk breast cancer tumors identified by the 70‐gene signature
por: Johansson, Annelie, et al.
Publicado: (2022)

Met and its ligand HGF are associated with clinical outcome in breast cancer
por: Veenstra, Cynthia, et al.
Publicado: (2016)

Akt kinases in breast cancer and the results of adjuvant therapy
por: Stål, Olle, et al.
Publicado: (2003)

Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer
por: Bostner, Josefine, et al.
Publicado: (2017)

Prognostic and Predictive Significance of Stromal Tumor-Infiltrating Lymphocytes (sTILs) in ER-Positive/HER2−Negative Postmenopausal Breast Cancer Patients
por: Pousette, Jenny, et al.
Publicado: (2022)

Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit
por: Bostner, Josefine, et al.
Publicado: (2012)

C–X–C ligand 10 and C–X–C receptor 3 status can predict tamoxifen treatment response in breast cancer patients
por: Hilborn, Erik, et al.
Publicado: (2014)

Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-α-negative breast cancer
por: Hilborn, Erik, et al.
Publicado: (2016)

PTPN2 deficiency along with activation of nuclear Akt predict endocrine resistance in breast cancer
por: Karlsson, Elin, et al.
Publicado: (2018)

Ephrin-B2 inhibits cell proliferation and motility in vitro and predicts longer metastasis-free survival in breast cancer
por: Magic, Zeljana, et al.
Publicado: (2019)

Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer
por: Jerevall, Piiha-Lotta, et al.
Publicado: (2010)

Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer
por: Nordenskjöld, Anna, et al.
Publicado: (2016)

17β-Hydroxysteroid Dehydrogenase Type 14 Is a Predictive Marker for Tamoxifen Response in Oestrogen Receptor Positive Breast Cancer
por: Sivik, Tove, et al.
Publicado: (2012)

Tamoxifen therapy benefit for patients with 70-gene signature high and low risk
por: van ‘t Veer, Laura J., et al.
Publicado: (2017)

EPH/ephrin profile and EPHB2 expression predicts patient survival in breast cancer
por: Husa, Anna-Maria, et al.
Publicado: (2016)

Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy
por: Nordenskjöld, Anna, et al.
Publicado: (2023)

Nucleases as molecular targets for cancer diagnosis
por: Balian, Alien, et al.
Publicado: (2021)

Revealing Different Roles of the mTOR-Targets S6K1 and S6K2 in Breast Cancer by Expression Profiling and Structural Analysis
por: Karlsson, Elin, et al.
Publicado: (2015)

Oestrogen receptor co-activator AIB1 is a marker of tamoxifen benefit in postmenopausal breast cancer
por: Weiner, M., et al.
Publicado: (2013)

Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer
por: Wegman, Pia, et al.
Publicado: (2007)

Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer
por: Schroeder, Brock, et al.
Publicado: (2017)

Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients
por: Wegman, Pia, et al.
Publicado: (2005)

ERBB2 and PTPN2 gene copy numbers as prognostic factors in HER2-positive metastatic breast cancer treated with trastuzumab
por: Ellegård, Sander, et al.
Publicado: (2019)

MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit
por: Løkkegaard, Sanne, et al.
Publicado: (2021)

High expression of stromal PDGFRβ is associated with reduced benefit of tamoxifen in breast cancer
por: Paulsson, Janna, et al.
Publicado: (2016)

Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer
por: Lindström, Linda S, et al.
Publicado: (2018)

Time dependent effects of adjuvant tamoxifen therapy on cerebrovascular disease: results from a randomised trial
por: Rosell, J, et al.
Publicado: (2011)

MD#1182: Calibration of diamond particle detectors in IP6
por: Valette, Matthieu, et al.
Publicado: (2017)

Flow cytometric analysis of S-phase fraction in breast carcinomas using gating on cells containing cytokeratin. South East Sweden Breast Cancer Group.
por: Wingren, S., et al.
Publicado: (1994)

Inactivation of FBXW7/hCDC4-β expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer
por: Akhoondi, Shahab, et al.
Publicado: (2010)

Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up
por: Lundgren, Christine, et al.
Publicado: (2020)

Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients
por: Pérez-Tenorio, G, et al.
Publicado: (2002)

AKT-1 and BCL-2 co-expression in breast cancer patients correlates with better survival
por: Pérez-Tenorio, G, et al.
Publicado: (2000)

IP6K gene identification in plant genomes by tag searching
por: Fassetti, Fabio, et al.
Publicado: (2011)

The Role of MicroRNA-200 in Progression of Human Colorectal and Breast Cancer
por: Bojmar, Linda, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_kr1j4iqiq5djh3k8oftnsjp95o